Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Maxcyte (MXCT) Other Operating Expenses (2020 - 2025)

Maxcyte (MXCT) has disclosed Other Operating Expenses for 6 consecutive years, with -$12.4 million as the latest value for Q3 2025.

  • On a quarterly basis, Other Operating Expenses rose 4.89% to -$12.4 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$29.4 million, a 8.05% decrease, with the full-year FY2024 number at $30.8 million, down 0.5% from a year prior.
  • Other Operating Expenses was -$12.4 million for Q3 2025 at Maxcyte, up from -$13.6 million in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $8.3 million in Q4 2023 to a low of -$13.6 million in Q2 2025.
  • A 5-year average of $68278.9 and a median of $4.3 million in 2022 define the central range for Other Operating Expenses.
  • Peak YoY movement for Other Operating Expenses: surged 68.18% in 2023, then crashed 261.59% in 2024.
  • Maxcyte's Other Operating Expenses stood at $4.5 million in 2021, then skyrocketed by 38.85% to $6.3 million in 2022, then surged by 32.14% to $8.3 million in 2023, then decreased by 9.28% to $7.5 million in 2024, then plummeted by 265.7% to -$12.4 million in 2025.
  • Per Business Quant, the three most recent readings for MXCT's Other Operating Expenses are -$12.4 million (Q3 2025), -$13.6 million (Q2 2025), and -$10.9 million (Q1 2025).